Empagliflozin Scores Topline Win in EMPA-KIDNEY Trial

Researchers stopped the 6600-patient EMPA-KIDNEY trial sooner than expected because it positively met prespecified efficacy criteria in a trial of patients with CKD with or without diabetes.
Medscape Medical News

source https://www.medscape.com/viewarticle/970434?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost